ITRAQ Coupled with 2DLC-MS/MS to Screen and Identify Speci-fic Bio-markers of T-Cell Acute Lymphoblastic Leukemia.

Wen-Li ZUO; Run-Hong YU; Jing-Yu ZHANG; Mei DENG; Yu-Feng LIU

Return

ITRAQ Coupled with 2DLC-MS/MS to Screen and Identify Speci-fic Bio-markers of T-Cell Acute Lymphoblastic Leukemia.

VernacularTitle:同位素标记联合二维液相色谱串联质谱技术筛选T淋巴细胞急性白血病特异标记物
Author: Wen-Li ZUO ¹ ; Run-Hong YU ² ; Jing-Yu ZHANG ² ; Mei DENG ¹ ; Yu-Feng LIU ^{3
,

4}
Author Information

1. Department of Hematology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou 450003, Henan Province, China.
2. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China.
3. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China . E-mail: lyf6012@
4. net.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2018;26(1):77-82
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo screen and identify potential biomarkers specific for T-cell acute lymphoblastic leukemia (T-ALL).
METHODSSera were collected from 20 newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) patients and 20 T-ALL patients. Proteins were extracted, purified and digested with trypsin. All specimens were analyzed by isobaric tags for relative and absolute quantification (iTRAQ) and two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) in a data-dependent mode. Enzyme-linked immunosorbent assay (ELISA) was used to analyze the expression of serum soluble L-selectin (sL-selectin).
RESULTSA total of 468 proteins were identified from distinct peptides. Compared with B-ALL group, 31 proteins were significantly differentially up-regulated while 7 proteins were significantly down-regulated in T-ALL group, sL-selectin was the higher up-regulated in these differential expression proteins. The overexpression of sL-selectin in T-ALL was verified by ELISA.
CONCLUSIONThere are the differentially expressed proteins between T-ALL and B-ALL, and the sL-selectin is specific for T-ALL, which can not only become a new biomarker for the diagnosis and prognosis of T-ALL, but also can be used as a potential target for therapy of this leukemia.